European commission approves adcetris® (brentuximab vedotin) for the treatment of adult patients with previously untreated cd30+ stage iii hodgkin lymphoma in combination with avd

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the european commission (ec) approved adcetris® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (avd) to treat adult patients with previously untreated cd30+ stage iii hodgkin lymphoma. adcetris is an antibody-drug conjugate (adc) directed at cd30, a defining marker of hodgkin lymphoma, and has been previously approved as a therapy for adult patients in europe in.
TAK Ratings Summary
TAK Quant Ranking